Private Label Cosmetics In Canada: Responsibilities For Importers And Brand Owners

Selling private‑label cosmetics in Canada means you and your importer share compliance. Notify Health Canada within 10 days of first sale, label to Canadian rules (bilingual, INCI), screen formulas against the Cosmetic Ingredient Hotlist, and amend when anything material changes. As of March 5, 2025, the Cosmetic Notification Form (CNF) requires a Canadian address for the manufacturer or the importer. If you’re importing finished goods from overseas, appoint a Canadian importer of record and align roles before the first shipment.

Who’s On The Hook For What (Importer Vs. Brand Owner)

Under Canada’s Cosmetic Regulations, an importer is the person who brings a cosmetic into Canada for sale, and the manufacturer includes a Canadian responsible person if the foreign manufacturer has no Canadian address. In practice, a brand that imports finished goods may wear both hats unless you appoint a Canadian importer of record.

For private‑label programs, split duties early. The importer manages Canadian-facing items, including being listed in Section 4 of the CNF. The brand owner steers formulation, claims, and supply chain. When roles overlap, Health Canada expects the highest party in the distribution chain to be designated appropriately on the CNF and for all contacts to be complete and accurate.

Bottom line: your responsibilities are shared but not optional. Both parties are accountable for compliant formulation, labelling, and notification. If a third party files on your behalf, Health Canada still requires the manufacturer/importer contact details inside the CNF.

Core Legal Duties You Can’t Outsource

You must notify Health Canada within 10 days after first sale and amend within 10 days when your brand name, contact details, or formula changes. When you discontinue sale, the CNF must be updated within the same 10‑day window. This is how Health Canada tracks what’s on the market and who is responsible for it.

You must label to Canadian rules. That includes product identity, net quantity (metric), dealer contact details, and any warnings/directions in English and French. Ingredients must appear in INCI format on the label.

You must screen every ingredient against Health Canada’s Cosmetic Ingredient Hotlist and respect prohibitions, restrictions, and any warning statements. Products exceeding Hotlist limits are considered non‑compliant and may face enforcement.

H2: Responsibility Split For Private‑Label Programs (Table)

Task	Importer Of Record	Brand Owner	Contract Manufacturer	Evidence To Keep
Screen formula against Hotlist	Lead or verify	Provide full formula	Provide full formula	INCI list; Hotlist checks; supplier specs
CNF: New, Amendment, Discontinue	File or co‑file; keep 10‑day rule	Approve data	Supply data	CNF PDFs; submission numbers
Canadian address on CNF (Sec. 4)	Provide importer address	N/A unless manufacturer in Canada	N/A unless designated	CNF Section 4 record; label contact sheet
Label build: bilingual, INCI, warnings	Verify and localize	Approve artwork	Supply artwork base	Final label proofs; French translation; claims matrix
Fragrance allergen disclosure	Plan timing; update labels	Align SKUs and print runs	Supply IFRA data	Timeline plan; revised labels; CNF updates
Change control after launch	Track triggers; file amendments	Authorize changes	Communicate changes	Change log; amended CNFs
Complaint and recall readiness	Maintain Canadian records	Support investigations	Provide batch docs	SOPs; complaint log; CAPA notes

Note on fragrance allergens: Canada phases in disclosure: 24 allergens from April 12, 2026; expanded list from August 1, 2026 for new products; and August 1, 2028 for existing products. Plan inventory and artwork accordingly.

Before Your First Shipment: Do These Six Things

1. First, confirm classification and claims. If your product strays into a drug or natural health product claim, you’re in the wrong framework. Use plain, cosmetic‑appropriate language and avoid therapeutic claims.
2. Second, screen the INCI list against the Hotlist and capture concentration caps and required warnings. This is a non‑negotiable pre‑import step and will influence both labels and CNF entries.
3. Third, build the label set correctly. You need identity, net quantity in metric, dealer details, bilingual warnings/directions (if required), and a proper INCI list. Lock in translations before artwork.
4. Fourth, prepare and file the CNF. File within 10 days of first sale; pre‑sale filing is smart to prevent retail holds. Ensure Section 4 includes a Canadian address for the manufacturer or the importer.
5. Fifth, plan for fragrance allergen disclosure against the 2026–2028 schedule. Align print runs and retailer resets so you don’t scrap inventory. Track presence and thresholds in both labels and CNFs.
6. Sixth, lock change control. Any change to brand name, contact info, or formula triggers an amendment within 10 days. Assign one person to own the calendar and submission files.

Together, these steps prevent the common problems: shipment delays, relabelling, retailer penalties, and forced pullbacks. They also shorten your first‑purchase‑order to shelf timeline because retailers see fewer surprises.

After Launch: Staying Compliant In Canada

Amend Your CNF When Anything Material Changes

CNFs are not “set and forget.” When you tweak a formula, rename the brand, or update company details, you must amend the CNF within 10 days. Keep your submission numbers and saved CNF files organized so amendments take minutes, not days.

Tie this to your internal change‑control SOP. Route supplier change notices to regulatory, and require a Hotlist re‑check whenever an ingredient shifts. Build a short checklist for product managers so marketing changes don’t get ahead of regulatory obligations.

Label Upkeep Through The Fragrance Allergen Phases

Canada’s schedule is clear: 24 fragrance allergens by April 12, 2026; expanded list for new products by August 1, 2026; legacy SKUs by August 1, 2028. Map your inventory and dies to those dates and plan for staggered artwork. If you export to the EU, align disclosures where possible to avoid duplicate SKUs.

Update both the physical label and the CNF when allergens cross thresholds. Capture IFRA certificates and supplier declarations in your technical file. That way, you can substantiate disclosures if Health Canada asks.

Monitor Safety And Complaints

Keep a simple complaint log, including batch numbers and corrective actions. If an issue points to labelling or formulation, be ready to reformulate, relabel, or discontinue quickly. Health Canada may request labels, safety evidence, or other actions during follow‑up.

Set recall readiness now. Define who decides, how you notify retailers, and what documentation will be maintained with recalled lots. A clean paper trail protects market access and reputation.

Common Private‑Label Pitfalls

1. Copying EU or US labels without Canadian bilingual elements, INCI formatting, or dealer details is the fastest way to trigger relabelling. Build to Canadian rules from day one.
2. Missing the Canadian address requirement on the CNF after March 5, 2025 stops submissions cold. Foreign brands without a Canadian address need a Canadian importer or responsible person on the form.
3. Over‑notifying or under‑notifying wastes time. Health Canada allows a single CNF to cover a line or product when the base formulation is the same and only colour/fragrance/flavour changes, the product name is the same, and all other details match; otherwise, submit distinct CNFs.

How Progress Therapeutics Helps You Avoid Misses

We serve as your Canadian importer of record and manage CNF filings, ingredient reviews, and retailer‑ready documentation. We coordinate labels, translations, and fragrance allergen timing so you ship once and ship right. For you, that means cleaner launches and fewer repacks.

Progress Therapeutics has been in business since 2012. We are a leading Canadian importer of record for Health Canada‑regulated products. We hold a Drug Establishment Licence (DEL) for prescription and OTC, a Site Licence (SL) for natural health products, and a Medical Device Establishment Licence (MDEL) for medical devices. For cosmetics, there is no pre‑market approval, but regulators still expect diligence and documentation.

If you need a partner that handles Health Canada requirements end‑to‑end, Progress is your answer.

FAQs